New biobank aims to unlock secrets of lung scarring diseases
NCT ID NCT05392881
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study is creating a registry and biobank for people with interstitial lung diseases (ILD), including sarcoidosis, idiopathic pulmonary fibrosis, and hypersensitivity pneumonitis. Researchers will collect medical data and biological samples from up to 1,000 participants to support future studies. The goal is to better understand these lung conditions and potentially improve diagnosis and treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this biobank could provide valuable data and samples to help researchers discover new insights into interstitial lung diseases.
- What could go wrong
- This is an observational study that does not test any treatment, so it will not directly benefit participants. The collected data may not lead to immediate breakthroughs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERSENSITIVITY PNEUMONITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Heart scans may unlock hidden risks in minority communities
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can arm workouts boost oxygen use in lung disease?
- Can umbilical cord stem cells ease a scarring lung disease?